Aspire and LG Health are working together as Aspire
Ventures Precision Medicine Fund (AVP) General
Partners to realize the promise of precision medicine.
How We Measure Our Impact
Traditional process vs. AVP’s process: With a repeatable
process and in-house accelerators, AVP drastically reduces the
time and capital required to get innovative products to market.
An End-to-End Ecosystem for Accelerated Healthcare Innovation
Our fund’s unique structure equips ventures with an ecosystem of strategic partnerships and accelerators for each step of the venture development process — from ideation, to clinical trials, to FDA approval, to market adoption, to insurance reimbursement — maximizing our capital efficiency to rapidly advance new precision medicine technologies to market.
Clio Health is an all-in-one health campus that reimagines the corporate self-insured model. Built from the ground up to natively support technologies like AI, IoT, and blockchain, Clio Health is a technologically savvy early adopter for AVP ventures, giving them a fast track to market.